Biomarkers of sepsis: time for a reappraisal
Biomarkers of sepsis: time for a reappraisal
复制标题
DOI：
10.1186/s13054-020-02993-5
复制
发表时间：
2020-06-05
期刊：
影响因子：
15.1
通讯作者：
Vincent, Jean-Louis
中科院分区：
文献类型：
--
作者：
Pierrakos, Charalampos;Velissaris, Dimitrios;Vincent, Jean-Louis
脓毒症生物标志物具有重要的诊断、治疗和预后功能。在以前的综述中，我们确定了3370篇文献，报道了178种不同的与脓毒症相关的生物标志物。在本综述中，我们评估了脓毒症生物标志物的研究进展。MethodsUsing相同的方法，在我们以前的审查，我们搜索了PubMed数据库，从2009年到2019年9月使用术语“生物标志物”和“脓毒症。“没有年龄或语言的限制，所有的研究，临床和实验，包括在内。ResultsWe共检索到5367新的参考文献，因为我们以前的审查。我们确定了258种生物标志物，其中80种与我们之前的列表相比是新的。大多数生物标志物在不到5项研究中进行了评估，其中81项（31%）仅在一项研究中进行了评估。除了C-反应蛋白（CRP）或降钙素原（PCT）的研究外，在300多名参与者的临床研究中仅评估了26种生物标志物。40种生物标志物与PCT和/或CRP的诊断价值进行了比较; 9种生物标志物对脓毒症的诊断价值优于这两种生物标志物中的一种或两种。四十四个生物标志物已被评估的作用，在回答一个特定的临床问题，而不是他们的一般诊断或预后性质在sepsis.ConclusionsThe被确定的生物标志物的数量仍在增加，虽然在一个缓慢的速度比过去。大多数生物标志物尚未得到充分研究;特别是，需要更好地评估这些生物标志物的临床作用。
IntroductionSepsis biomarkers can have important diagnostic, therapeutic, and prognostic functions. In a previous review, we identified 3370 references reporting on 178 different biomarkers related to sepsis. In the present review, we evaluate the progress in the research of sepsis biomarkers.MethodsUsing the same methodology as in our previous review, we searched the PubMed database from 2009 until September 2019 using the terms "Biomarker" AND "Sepsis." There were no restrictions by age or language, and all studies, clinical and experimental, were included.ResultsWe retrieved a total of 5367 new references since our previous review. We identified 258 biomarkers, 80 of which were new compared to our previous list. The majority of biomarkers have been evaluated in fewer than 5 studies, with 81 (31%) being assessed in just a single study. Apart from studies of C-reactive protein (CRP) or procalcitonin (PCT), only 26 biomarkers have been assessed in clinical studies with more than 300 participants. Forty biomarkers have been compared to PCT and/or CRP for their diagnostic value; 9 were shown to have a better diagnostic value for sepsis than either or both of these biomarkers. Forty-four biomarkers have been evaluated for a role in answering a specific clinical question rather than for their general diagnostic or prognostic properties in sepsis.ConclusionsThe number of biomarkers being identified is still increasing although at a slower rate than in the past. Most of the biomarkers have not been well-studied; in particular, the clinical role of these biomarkers needs to be better evaluated.